Eraquell Tabs, Ivermectin 20 mg, Chewable Tablets for Horses

Main information

  • Trade name:
  • Eraquell Tabs, Ivermectin 20 mg, Chewable Tablets for Horses
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Eraquell Tabs, Ivermectin 20 mg, Chewable Tablets for Horses
    Romania
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ivermectin
  • Therapeutic area:
  • Horses

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0330/001
  • Authorization date:
  • 30-06-2010
  • EU code:
  • UK/V/0330/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued11/09/2009 –AN00984/2008

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

EraquellTabs,20mgChewabletabletsforHorses

EquimelTabs,20mgChewabletabletsforHorses(ES,PT)

Eraquellvet.,20mgChewabletabletsforHorses(DK,FI,IS,NO,SE)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachchewabletabletof3300mgcontains:

Activesubstance

Ivermectin.............................................................................. 20 mg

Forfulllistofexcipientsseesection6.1.

3. PHARMACEUTICALFORM

Chewabletablet.

White,circular,biconcavetabletwithbrownspots.

4. CLINICALPARTICULARS

4.1 Targetspecies

Horses

4.2 Indicationsforuse,specifyingthetargetspecies

Forthetreatmentofnematodeandarthropodinfestations,duetoadultandimmatureroundwormsand

botsinhorses:

Nematodes

Large-strongyles:

Strongylusvulgaris(adultandarteriallarvae)

Strongylusedentatus(adultandL4tissuelarvalstages)

Strongylusequinus(adultandL4larvalstage)

Triodontophorusspp.(adult)

Small-strongyles:

Cyathostomum(adultandnon-encystedmucosallarvae):Cylicocyclusspp.,Cylicostephanus

spp.,Gyalocephalusspp.

Parascaris:Parascarisequorum(adultandlarvae).

Oxyuris:Oxyurisequi(adultandlarvae).

Trichostrongylus:Trichostrongylusaxei(adult).

Dipteraninsects:Gasterophilusspp.(larvae).

Issued11/09/2009 –AN00984/2008

4.3Contraindications

Donotuseinfoalsunder2weeksofage.

Donotuseinhorsesknowntobehypersensitivetotheactiveingredientoranyoftheotheringredients.

4.4 Specialwarningsfortargetspecies

Careshouldbetakentoavoidthefollowingpracticesbecausetheyincreasetheriskof

developmentofresistanceandcouldultimatelyresultinineffectivetherapy:

- toofrequentandrepeateduseofanthelminticsfromthesameclassoveranextendedperiodof

time,

- underdosing,whichmaybeduetounderestimationofbodyweight,misadministrationofthe

product,orlackofcalibrationofthedosingdevice(ifany).

Suspectedclinicalcasesofresistancetoanthelminticsshouldbefurtherinvestigatedusing

appropriatetests(e.g.FaecalEggCountReductionTest).Wheretheresultsofthetest(s)strongly

suggestresistancetoaparticularanthelmintic,ananthelminticbelongingtoanotherpharmacological

classandhavingadifferentmodeofactionshouldbeused.

ResistancetoivermectinhasbeenreportedinParascarisequoruminhorses.Thereforetheuseof

thisproductshouldbebasedonlocal(regional,farm)epidemiologicalinformationabout

susceptibilityofnematodesandrecommendationsonhowtolimitfurtherselectionforresistanceto

anthelmintics.

Theproductissafeforuseinstallions.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Avermectinsmaynotbewelltoleratedinnontargetspecies.Casesofintolerancearereportedindogs,

especiallyCollies,OldEnglishSheepdogsandrelatedbreedsorcrosses,andalsointurtlesand

tortoises.

Dogsandcatsshouldnotbeallowedtoingestspilledtabletsorhaveaccesstousedpackagingdueto

thepotentialforadverseeffectsrelatedtoivermectintoxicity.

Youngfoals,miniaturehorsesandtoybreedsweighinglessthan50kgmaybeunabletoingesttablets.

Seektheadviceofyourveterinarysurgeon.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Washhandsafteruse.Avoidcontactwiththeeyes.Incaseofeyeirritation,seekmedicalattention.

Donoteat,drinkorsmokewhilehandlingthisproduct.Intheeventofaccidentalingestion,seek

medicaladviceandshowtheleaflettothephysiciansothatheknowswhatyouhavetaken.

4.6 Adversereactions(frequencyandseriousness)

Colic,diarrhoeaandanorexiahavebeenreportedinveryrareoccasionsposttreatment,inparticular

whenthereisheavywormburden.Inveryrareoccasions,allergicreactionssuchashypersalivation,

lingualoedema,urticaria,tachycardia,congestedmucusmembranes,andsubcutaneousoedemahave

beenreportedfollowingtreatmentwiththeproduct.

Issued11/09/2009 –AN00984/2008

4.7 Useduringpregnancy,lactationorlay

Canbeusedduringpregnancyandlactation.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9 Amountstobeadministeredandadministrationroute

Singleoraladministration.

200µgofivermectinperkgofbodyweightcorrespondingto1tabletper100kgbodyweight.

Weight Dosage Weight Dosage

Upto100kg 1tablet 401-500kg 5tablets

101-200kg 2tablets 501-600kg 6tablets

201-300kg 3tablets 601-700kg 7tablets

301-400kg 4tablets 701-800kg 8tablets

Toensureacorrectdosage,bodyweightshouldbedeterminedasaccuratelyaspossible.

Oncethecorrectdosehasbeendetermined,itshouldbeadministeredinthefollowingway:

Presentthetabletinthepalmofyourhand.

Presentingonetabletatatimemakesiteasierforthehorsetoacceptit,howevertheadministrationof

multipletabletsatonceisalsopossible.

Repeatthisgestureuntilthecompletedosehasbeenadministered.

Duringtheinitialadministration,thetabletcanbecombinedwithasmallamountoffoodoratreatto

increasetheacceptancebythehorse.

Intheeventthattherequireddoseisnotingestedanalternativetreatmentshouldbeadministered.

Seektheadviceofyourveterinarysurgeon.

Theveterinarysurgeonshouldgiveadviceregardingappropriatedosingprogrammesandstock

managementtoachieveadequateparasitecontrolforbothroundwormandbotinfestations.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Atolerancestudyperformedwiththeproductinadulthorseswithdosesupto5timesthe

recommendeddosagedidnotshowanyadversereactions.

Safetystudieswereconductedwithaveterinarymedicinalproductcontainingpraziquantelandthe

samedoseofivermectin(EQUIMAXoralgel),inmares,stallionsandfoals.

Administrationtomaresat3timestherecommendeddosageat14-dayintervalsduringthewhole

gestationandlactationperiodsdidnotresultinanyabortion,noranyadverseeffectduringgestation,at

parturitionoronthemaresgeneralhealth,noranyabnormalityinthefoals.

Administrationtostallionsat3timestherecommendeddosagedidnotshowanyadverseeffectin

particularonthereproductiveperformances.

Administrationtofoalswithdosesupto5timestherecommendeddosagedidnotshowanyadverse

reaction.

4.11Withdrawalperiod(s)

Meatandoffal:35days.

Issued11/09/2009 –AN00984/2008

Notauthorisedforuseinlactatinganimalsproducingmilkforhumanconsumption.

Issued11/09/2009 –AN00984/2008

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Endectocides,ivermectin.

ATCvetcode:QP54AA01

5.1 Pharmacodynamicproperties

Ivermectinisamacrocyclic-lactonederivativewhichhasabroadantiparasiticactivityagainst

nematodesandarthropods.Itactsbyinhibitingnerveimpulses.Itsmodeofactionincludesthe

glutamate-gatedchlorideionchannels.Ivermectinbindsselectivelyandwithhighaffinitytoglutamate-

gatedchlorideionchannelswhichoccurininvertebratenerveandmuscle cells.Thisleadstoan

increaseinthepermeabilityofthecellmembranetochlorideionswithhyperpolarisationofthenerveor

musclecell,resultinginparalysisanddeathoftherelevantparasites. Compoundsofthisclassmayalso

interactwithotherligand-gatedchloridechannels,suchasthosegatedbytheneurotransmittergamma-

aminobutyricacid(GABA).Thehighmarginofsafetyforcompoundsofthisclassisattributabletothe

factthat,inmammals,glutamatereceptorsinchlorideionchannelsdonotoccur;themacrocyclic

lactoneshavealowaffinitytoothermammalianligand-gatedchlorideionchannelsandtheydonot

readilycrosstheblood-brainbarrier.

5.2 Pharmacokineticparticulars

Afteroraladministrationoftheproductattherecommendeddosagetohorses,theivermectinpeak

plasmaconcentrationofaround14ng/mL(C

)wasreachedataTmaxof9

6h.andtheoral

meanabsolutebioavailabilityofivermectinisaround16%.

Theterminalhalf-lifevariesbetween2and5daysaftervariousroutesofadministrations.Ivermectinis

apoorlymetabolisedcompound.Duetoitslipophilicnature,ivermectinisexcretedinbileandultimately

eliminatedfromthebodyviathefaeces.Inhorses,about75%oftheadministereddoseisexcretedvia

thefaecesafteranoraladministrationofivermectinattherecommendeddose.Moreover90%of the

totaldrugisexcretedwithin4dayspost-administration.Approximately2%ofunchangedivermectin

andmetabolitesareexcretedinurine.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Povidone

Crospovidone

Cellulose,microcrystalline

CiderApplemarc(pressedapplepulp)

Glucose,liquid

Starch,pregelatinised(maizestarch)

Compressiblesugar

Magnesiumstearate

6.2 Incompatibilities

Notapplicable.

6.3 Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:36months

Shelflifeafterfirstopeningtheimmediatepackaging:12months

6.4.Specialprecautionsforstorage

Issued11/09/2009 –AN00984/2008

Thisveterinarymedicinalproductdoesnotrequireanyspecialstoragecondition.

Issued11/09/2009 –AN00984/2008

6.5 Natureandcompositionofimmediatepackaging

Cartonboxcontaining1,2,12,40or48polypropylenetubesof8tabletsclosedbyapolyethylenechild

proofcap.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductorwaste

materialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.EXTREMELYDANGEROUS

TOFISHANDAQUATICLIFE.Donotcontaminatesurfacewatersorditcheswiththeproductor

usedcontainer.

7. MARKETINGAUTHORISATIONHOLDER

VIRBAC-1 ère Avenue–2065mL.I.D,06516Carros,Cedex,France

8. MARKETINGAUTHORISATIONNUMBER

Vm05653/4159

9. DATEOFFIRSTAUTHORISATION

11September2009

10 DATEOFREVISIONOFTHETEXT

11September2009

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

20-11-2018

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

FDA - U.S. Food and Drug Administration

24-10-2018

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling all products lots manufactured from February 27, 2018 through July 20, 2018, as a precaution because they have the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

22-6-2018

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

FDA - U.S. Food and Drug Administration

2-5-2018

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

FDA - U.S. Food and Drug Administration

26-11-2018

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health technologies.

FDA - U.S. Food and Drug Administration

4-9-2018

Agenda:  Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda: Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda of CHMP written procedure*20-23 August 2018

Europe - EMA - European Medicines Agency

22-8-2018

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye:  http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz . pic.twitter.com/ecJErFeiSH

FDA - U.S. Food and Drug Administration

20-7-2018

Agenda:  Agenda - CAT agenda of the 18-20 July 2018 meeting

Agenda: Agenda - CAT agenda of the 18-20 July 2018 meeting

Committee for Advanced Therapies (CAT) agenda for the meeting on 18-20 July 2018

Europe - EMA - European Medicines Agency

29-6-2018

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit  https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFriday pic.twitter.com/JWK672XtdI

FDA - U.S. Food and Drug Administration